PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
June 10, 2024 07:00 ET
|
PolyPid Ltd.
Charles E. Edmiston, Ph.D., Emeritus Professor of Surgery, Medical College of Wisconsin, to discuss the significant unmet medical need in surgical site infections preventionCompany to Provide an...
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 08, 2024 07:00 ET
|
PolyPid Ltd.
More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded...
PolyPid to Participate in Citizens JMP Life Sciences Conference
May 01, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
April 30, 2024 07:00 ET
|
PolyPid Ltd.
Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line...
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
April 24, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
February 28, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024 07:00 ET
|
PolyPid Ltd.
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once...
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
February 12, 2024 07:00 ET
|
PolyPid Ltd.
Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 ...
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
January 31, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
January 04, 2024 16:32 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...